Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Royalty Pharma (RPRX) and Syndax Pharmaceuticals (SNDX) announced that Royalty Pharma has entered into a $350M synthetic royalty funding ...

The Company announced a $350 million royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo. Under the agreement, Syndax received $350 million in exchange for a 13.8% ...

On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...

CET Biocartis appoints Randy Polonsky as Chief Financial Officer Mechelen, Belgium, 05 November 2024 – Biocartis NV ...

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.73 per share a year ago. These ...

STAT Plus: Medicare Advantage insurers ramped up use of technology to deny claims, Senate investigation shows ...

Gland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 26,539.86 Crore) operating in Pharmaceuticals sector. Gland Pharma Ltd. key Products/Revenue ...

Two tragic incidents in Phuket resulted in the drowning deaths of a five year old Chinese boy and a 43 year old British tourist, police confirmed yesterday. Karon Police were notified by Chalong ...